These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9768823

  • 1. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [Abstract] [Full Text] [Related]

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 3. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M, Vici P.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [Abstract] [Full Text] [Related]

  • 4. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K, Bates M, Lieu D, Arundell E, Williamson T, Zagari M.
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [Abstract] [Full Text] [Related]

  • 5. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [Abstract] [Full Text] [Related]

  • 6. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [Abstract] [Full Text] [Related]

  • 7. Overview and historical development of dexrazoxane.
    Hellmann K.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [Abstract] [Full Text] [Related]

  • 8. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML, Moiceenko VM, Orlova RV.
    Vopr Onkol; 1993 Aug; 39(1-3):26-32. PubMed ID: 8073671
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Lemez P, Maresová J.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
    [Abstract] [Full Text] [Related]

  • 10. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR, Spencer CM.
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [Abstract] [Full Text] [Related]

  • 11. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
    FitzPatrick WM, Dervisis NG, Kitchell BE.
    Vet Comp Oncol; 2010 Dec; 8(4):273-82. PubMed ID: 21062409
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [Abstract] [Full Text] [Related]

  • 13. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
    Mladosievicova B, Foltinová A, Petrásová H, Bernadic M, Hulín I.
    Neoplasma; 2001 Sep; 48(1):61-5. PubMed ID: 11327539
    [Abstract] [Full Text] [Related]

  • 16. Cardiotoxicity and cardioprotection in breast cancer chemotherapy. The role of dexrazoxane.
    Venturini M.
    Clin Ter; 1998 Sep; 149(921):5-6. PubMed ID: 9621480
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL.
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [Abstract] [Full Text] [Related]

  • 19. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Blum RH.
    Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.